9 assets in Minimally Invasive Lung Adenocarcinoma

Therapeutic assets addressing Minimally Invasive Lung Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Minimally Invasive Lung Adenocarcinoma	NRG Oncology	P2	BB (67)
Cis-Diamminedichloroplatinum Ii Minimally Invasive Lung Adenocarcinoma	National Cancer Institute (NCI)	P2	B (60)
Docetaxel Minimally Invasive Lung Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Etoposide Minimally Invasive Lung Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Minimally Invasive Lung Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivestim Minimally Invasive Lung Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Minimally Invasive Lung Adenocarcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Pegfilgrastim Minimally Invasive Lung Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Veliparib Minimally Invasive Lung Adenocarcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)